S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

DMAC DiaMedica Therapeutics Inc

4.15

0.14 (3.49%)

19 Nov 2024 - Closed

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

DiaMedica Therapeutics (NASDAQ:DMAC)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more DiaMedica Therapeutics Charts.

DiaMedica Therapeutics (NASDAQ:DMAC)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more DiaMedica Therapeutics Charts.

DiaMedica Therapeutics Inc News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 14 November 2024 (5 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 14 November 2024 (5 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 8 August 2024 (3 months ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 8 August 2024 (3 months ago) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Friday 19 July 2024 (4 months ago) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Friday 19 July 2024 (4 months ago) • Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933
Thursday 11 July 2024 (4 months ago) • Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Tuesday 9 July 2024 (4 months ago) • Edgar (US Regulatory)

DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
Monday 1 July 2024 (5 months ago) • Business Wire

DiaMedica Therapeutics Announces $11.8 Million Private Placement
Wednesday 26 June 2024 (5 months ago) • Business Wire

DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
Wednesday 26 June 2024 (5 months ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 4 June 2024 (6 months ago) • Edgar (US Regulatory)

More DiaMedica Therapeutics Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions